Abiopharma

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Geron Corporation Provides 2026 Financial Guidance

Geron Corporation Provides 2026 Financial Guidance

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026